GLP-1 & compounded medication availability in South Carolina (2026)
South Carolina’s pharmacy rules themselves are close to the national baseline: licensure, USP-aligned compounding standards, a nonresident permit for out-of-state pharmacies. What sets the state apart is its Attorney General, who opened 2025 with a consumer alert on unapproved and compounded weight-loss products and then co-led a 37-state coalition pressing the FDA over counterfeit GLP-1 drugs. Neither action restricts a patient-specific prescription filled by a permitted pharmacy; both are reasons to buy only from sellers who show their sourcing. Every row below is the honest version of that answer.
What ships to South Carolina: all ten lines
| Product line | Available in South Carolina? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Filled on patient-specific prescriptions by pharmacies holding the state’s nonresident permit. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | Same flow and same permit requirement as the semaglutide row. |
| NAD+ | Yes | 8–10 business days | Ships from licensed partner pharmacies permitted for South Carolina. |
| Sermorelin | Yes | 8–10 business days | Longevity family; nothing state-specific applies. |
| Glutathione | No | N/A | Not in the OrderlyMeds formulary today. |
| BPC-157 | Yes | 8–10 business days | Compounded injectable. Its federal record is below. |
| TB-500 | Yes | 8–10 business days | Compounded injectable; read its section before ordering. |
| KPV | No | N/A | Not carried anywhere; our peptide lines are injectables only. |
| Epitalon | Yes | 8–10 business days | Compounded injectable; federal picture below. |
| MOTS-c | Yes | 8–10 business days | Compounded injectable; its federal record is its own, below. |
Unavailable rows stay on this table on purpose, because an honest No beats a padded catalog. South Carolina facts were last reviewed on November 16, 2026.
Research peptides in South Carolina: BPC-157, TB-500, KPV, Epitalon & MOTS-c
BPC-157, TB-500, Epitalon and MOTS-c are in the OrderlyMeds formulary for South Carolina, each compounded as an injectable on a patient-specific prescription; KPV is not, here or in any state, because we compound these lines as injectables only. The Attorney General’s January 2025 alert warned specifically about weight-loss compounds sold without prescriptions or medical supervision, the opposite of how these lines are dispensed, and the sections below add the federal record for each substance, stated whether or not the line ships to you.
BPC-157 in South Carolina
BPC-157 ships to South Carolina addresses as a compounded injectable, dispensed on a patient-specific prescription. Both federal facts below apply to it unchanged.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in South Carolina
South Carolina orders for TB-500 are filled as compounded injectables on patient-specific prescriptions. Its federal record follows.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in South Carolina
KPV is not in our catalog for South Carolina or any other state. We compound these peptide lines as injectables only, and KPV is not carried in that form.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in South Carolina
Epitalon reaches South Carolina addresses as a compounded injectable under a patient-specific prescription. Its federal standing is stated below.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in South Carolina
MOTS-c is dispensed to South Carolina as a compounded injectable on a patient-specific prescription. Its federal record is not the other four lines’, so read it on its own terms below.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What South Carolina’s pharmacy regulators and Attorney General say
South Carolina’s pharmacy oversight sits with a board under the Department of Labor, Licensing and Regulation, and in 2025 that board moved to deepen its compounding expertise by convening an advisory panel. The state’s loudest public statements on compounded medications, though, have come from the Attorney General, and they are consumer-protection warnings about unapproved sellers, not restrictions on patient-specific dispensing.
South Carolina regulates pharmacy compounding through the Pharmacy Practice Act and board-published inspection standards aligned to USP chapters, and in 2025 the board convened a Compounding Advisory Panel to advise on compounding practice and regulation; no GLP-1-specific or peptide-specific prohibition has been published by the board. Source: South Carolina Board of Pharmacy (LLR).
Out-of-state pharmacies shipping prescriptions to South Carolina patients must hold a nonresident pharmacy permit from the board. Source: South Carolina Board of Pharmacy (LLR).
On January 3, 2025, South Carolina’s Attorney General issued a consumer alert warning that unapproved and compounded tirzepatide and semaglutide products — sold as drops, lozenges, nasal sprays and patches, often without valid prescriptions or medical supervision — are not reviewed by FDA for safety, quality or effectiveness. Source: South Carolina Attorney General, January 3, 2025.
On February 19, 2025, the Attorney General co-led a 37-state coalition urging the FDA to act against counterfeit GLP-1 drugs and against online retailers selling active pharmaceutical ingredients directly to consumers under a “for research purposes only” label. Source: South Carolina Attorney General, February 19, 2025.
South Carolina permits prescribing on the basis of a telehealth encounter meeting the state’s standard of care. Source: Center for Connected Health Policy (CCHP) Policy Finder.
Read together, the record points one direction: South Carolina’s concern is sellers who skip prescriptions, fake approval status, or push research-chemical websites, not telehealth care built on individual evaluations and permitted pharmacies. A South Carolina order through OrderlyMeds follows the same path as every state: online eligibility check, evaluation by a South Carolina-licensed provider, fulfillment by a permitted partner pharmacy, national pricing.
South Carolina availability FAQs
Is compounded semaglutide available in South Carolina?
Yes. OrderlyMeds ships compounded semaglutide to South Carolina addresses on patient-specific prescriptions, filled by partner pharmacies holding the state’s nonresident permit. New customers start at $74/month for the first two months.
What has South Carolina’s Attorney General said about compounded weight-loss drugs?
Two things, both cited above: a January 2025 consumer alert about unapproved and compounded weight-loss products sold without prescriptions or medical supervision, and a February 2025 coalition letter urging FDA action on counterfeit GLP-1s and “research use only” ingredient sales. Both are warnings about how a product is sold, and neither restricts a patient-specific prescription.
Can I get BPC-157 or other research peptides shipped to South Carolina?
BPC-157, TB-500, Epitalon and MOTS-c ship to South Carolina as compounded injectables on patient-specific prescriptions; KPV does not, because we compound these lines as injectables only. Each section above carries that line’s own federal record, which applies wherever you buy.
How long does delivery to South Carolina take?
Our published window is 8–10 business days from signup.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
